Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: J Int Neuropsychol Soc. 2017 Oct 16;24(3):283–293. doi: 10.1017/S135561771700090X

Figure 3.

Figure 3

Vigilance decrement was observed in placebo- but not amphetamine-treated healthy human participants performing the Conners’ CPT-2 as measured by D′ (A), driven in part by changes in target responding (Hit Rate; B) and responses to non-targets (False Alarm Rate; C), across trial blocks. Reaction time and reaction time variability are presented in panels D and E, respectively. Asterisks represent a significant difference from block 1 performance (p < 0.05).